Click any tag below to further narrow down your results
+ investment
(1)
+ evaluation
(1)
+ bioinvestgpt
(1)
+ appeals
(1)
+ revenue cycle management
(1)
+ medical billing automation
(1)
+ insurance claim denials
(1)
+ korex
(1)
+ synthetic customers
(1)
+ cvs health
(1)
+ digital twin
(1)
+ inmyteam
(1)
+ pharmaceutical
(1)
+ drug discovery
(1)
+ disease prediction
(1)
Links
OpenAI is pitching agents that operate EHRs and payer portals by clicking and typing, so they can handle tasks like MRI authorization that APIs don't reach. The post shares evaluation results on helpfulness, safety, and cost, plus early deployments with Cigna, CVS Health, Abridge, and Ambience.
- A demo agent takes a patient's message and visit notes, pulls prior imaging and PT records from the EHR, and drafts an MRI order, encounter note, and patient reply for clinician review.
- CVS Health reports an agent cleared a months-long document-sending backlog over a weekend and handles system steps for tens of thousands of consults a day, with validation checks and human oversight.
- Cigna case managers previously had to navigate more than 10 separate systems to gather member context; computer use now pulls that together in seconds.
The Electronic Frontier Foundation filed a FOIA lawsuit to get records on WISeR, a Medicare program launched in January 2026 that uses AI to review prior authorization requests. The released documents include vendor contracts, accuracy and bias testing requirements, and status reports on how the program is running.
- WISeR uses AI to assess prior authorization requests from Medicare beneficiaries, and experts and lawmakers have warned it could cause serious patient harm, including wrongful denials of care.
- Little is public about how the algorithms work or what data they were trained on, and it is unclear whether safeguards exist against algorithmic bias or privacy violations.
- The released records include participation agreements with six tech companies, reviewer criteria, a data reporting guide on vendor audits, and an actuary estimate of the program's impact.
Copenhagen startup BioinvestGPT runs virtual versions of drug trials with its AI models, and it says its forecasts were right in five of six cases so far. The companies behind these tools hope that testing drugs in simulation first will help more of them succeed in real human studies.
- BioinvestGPT shared its predictions for several high-profile drug trials with Reuters in July, before those results were public.
- The firm has been correct in five of six of those forecasts so far, a small sample that still needs more track record to judge.
- The pitch is that better virtual trials could cut the failure rate of expensive human studies.
Insurance companies are using AI to automatically reject claims at scale, leaving medical practices buried in appeals work they can't handle. Korex is a startup building software to audit these rejections and generate policy-backed appeals automatically.
- Insurance carriers have replaced human claims adjusters with automated rejection systems, causing a spike in erroneous denials that practices lack resources to challenge
- Medical billing departments can't manually contest every denial, so millions in legitimate claims go unpaid or get shifted to patients as unexpected bills
- Korex's approach: automatically cross-reference denial codes against clinical charts and payer policies to generate verified appeals in one click, with a $299/month pricing model per clinic
CVS Health uses over 100,000 AI-driven “agentic twins” to run customer research in 15–30 minutes instead of weeks, achieving 85–95% accuracy and reaching hard-to-access groups. Built with Simile from 3 million consented responses, these simulations remain human-overseen to ensure proper prompting, validation, and governance before live rollouts.
- CVS runs 100,000+ AI "agentic twins" built from 3 million consented survey responses to simulate customer behavior, cutting research time from 4-6 weeks to 15-30 minutes with 85-95% accuracy versus live studies
- The twins let CVS probe hard-to-reach populations (like immunocompromised patients) and understand not just what customers do but why, using demographic and behavioral details tied to each twin
- Human oversight remains mandatory: leads review all prompts/results and investigate any deviation from expected outcomes to guard against bias and privacy risks
- CVS plans to expand the twin population for "dress rehearsals" of new services before real-world rollout
Nvidia Corp. will invest $1 billion over five years to establish a new artificial intelligence laboratory in collaboration with Eli Lilly & Co. The facility, located in Silicon Valley, aims to accelerate the application of AI in the pharmaceutical industry by leveraging Lilly's lab expertise.
- Nvidia will invest $1 billion over five years to build an AI drug discovery lab with Eli Lilly, located in Silicon Valley
- The lab will use Lilly's lab expertise combined with Nvidia's computational tools to predict how compounds interact with biological systems
- The goal is to speed up and cut costs in drug discovery while improving precision in targeting specific diseases
- The deal signals Nvidia's strategic push into healthcare as a growth area beyond its core computing and gaming business
SleepFM is a novel foundation model developed to analyze polysomnography (PSG) recordings, facilitating accurate predictions of various health conditions based on sleep data. Trained on over 585,000 hours of sleep recordings, it demonstrates strong performance in predicting diseases such as dementia and heart failure, while also supporting standard sleep analysis tasks.
- SleepFM was trained on over 585,000 hours of polysomnography recordings, an unusually massive dataset for this domain.
- The model predicts diverse downstream conditions like dementia and heart failure directly from raw sleep data, not just standard sleep-stage/apnea metrics.
- It performs well on conventional sleep analysis tasks while also generalizing to disease prediction, suggesting a single foundation model can replace many task-specific ones.
InMyTeam offers a comprehensive software solution designed to streamline operations for home care and health agencies, ensuring compliance with state regulations and simplifying tasks like claims management and patient assessments. With features powered by AI, the platform enhances efficiency and supports high-quality care, allowing agencies to focus on their patients.
- InMyTeam is software targeting home care and health agencies, focused on state regulatory compliance, claims management, and patient assessments
- The platform uses AI to boost efficiency and support care quality, letting agencies spend less time on admin and more on patients